Weight loss drug, 710GO, demonstrates efficacy in animal studies without GLP-1 side effects
Endevica Bio addresses shortcomings in the standard-of-care in a market with massive unmet need
Obese Adults in
the US
the US
Annual medical
expenditures
expenditures
of US Healthcare
Spending
Spending
Despite advances, existing treatments like GLP-1 agonists face challenges such as high cost, intolerability, and weight regain after discontinuation, leaving a gap in long-term solutions.
Endevica Bio addresses these challenges with novel, differentiated, melanocortin therapeutics.
“Endevica Bio is a disruptive force in a multibillion-dollar market championing the fight against one of America’s most
pressing health crises.”
Russell Potterfield, CEO – Endevica Bio
Developing safe and tolerable weight loss therapeutics
Endevica Bio is developing an obesity treatment designed to transform the weight loss industry through highly effective, safe, and less costly solutions compared to current GLP-1s. Our groundbreaking approach includes the development of melanocortin-4 receptor agonists. Our lead candidate, 710GO, represents a pivotal shift in weight loss treatment.